Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity

Journal of Cellular Physiology

Volumn 227, Issue 10, 2012, Pages 3389-3396

  Tesei, Anna ^a   Brigliadori, Giovanni ^a   Carloni, Silvia ^a   Fabbri, Francesco ^a   Ulivi, Paola ^a   Arienti, Chiara ^a   Sparatore, Anna ^b   Del Soldato, Piero ^c   Pasini, Alice ^d   Amadori, Dino ^a   Silvestrini, Rosella ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c CTG Pharma   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACS2; ACS33; CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; HYDROGEN SULFIDE; ORGANOSULFUR DERIVATIVE; UNCLASSIFIED DRUG; VALPROIC ACID DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL INVASION; CELL MEMBRANE DEPOLARIZATION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SENSITIZATION;

APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROGEN SULFIDE; LUNG NEOPLASMS; MITOCHONDRIA; VALPROIC ACID;

EID: 84862669889     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24039     Document Type: Article

References (54)

1. Awasthi S, Singhal SS, Singhal J, Cheng J, Zimniak P, Awasthi YC. 2003. Role of RLIP76 in lung cancer doxorubicin resistance: II. Doxorubicin transport in lung cancer by RLIP76. Int J Oncol 22: 713- 720.
2. Baskar R, Bian J. 2011. Hydrogen sulfide gas has cell growth regulatory role. Eur J Pharmacol 656: 5- 9.
3. Baylin SB, Ohm JE. 2006. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107- 116.
4. Benavides GA, Squadrito GL, Mills RW, Patel HD, Isbell TS, Patel RP, Darley-Usmar VM, Doeller JE, Kraus DW. 2007. Hydrogen sulfide mediates the vasoactivity of garlic. Proc Natl Acad Sci USA 104: 17977- 17982.
5. Boyle P, Levin B, editors. 2008. World cancer report 2008. Lyon, France: IARC Press.
6. Brownell JE, Allis CD. 1996. Special HATs for special occasions: Linking histone acetylation to chromatin assembly and gene activation. Curr Opin Genet Dev 6: 176- 184.
7. Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV. 2008. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. Br J Cancer 98: 1515- 1524.
8. Darzynkiewicz Z. 1994. Acid-induced denaturation of DNA in situ as a probe for chromatin structure. Methods Cell Biol 41: 527- 541.
9. Darzynkiewicz Z, Kapuscinski J. 1990. Acridine orange: A versatile probe of nucleic acids and other cell constituents. In: Melamed MR, Lindmo T, Mendelson ML, editors. Flow cytometry and sorting. 2nd ed. New York: Wiley - Liss. pp 291- 314.
10. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. 2008. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206- 222.
11. Eck SM, Hoopes PJ, Petrella BL, Coon CI, Brinckerhoff CE. 2009. Matrix metalloproteinase-1 promotes breast cancer angiogenesis and osteolysis in a novel in vivo model. Breast Cancer Res Treat 116: 79- 90.
12. Feinberg AP, Tyco B. 2004. The history of cancer epigenetics. Nat Rev Cancer 4: 143- 153.
13. Feinberg AP, Ohlsson R, Henikoff S. 2006. The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21- 33.
14. Folmer Y, Schneider M, Blum HE, Hafkemeyer P. 2007. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther 14: 875- 884.
15. Gasperi-Campani A, Roncuzzi L, Ricotti L, Lenzi L, Gruppioni R, Sensi A, Zini N, Zoli W, Amadori D. 1998. Molecular and biological features of two new human squamous and adenocarcinoma of the lung cell lines. Cancer Genet Cytogenet 107: 11- 20.
16. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T. 2001. Valproic acid derivatives: A novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969- 6978.
17. Ibrahim T, Zoli W, Frassineti GL, Tesei A, Colantonio I, Monti M, Amadori D. 2005. Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non-small cell lung cancer: A phase I study. Lung Cancer 47: 261- 267.
18. Isenberg JS, Jia Y, Field L, Ridnour LA, Sparatore A, Del Soldato P, Sowers AL, Yeh GC, Moody TW, Wink DA, Ramchandran R, Roberts DD. 2007. Modulation of angiogenesis by dithiolethionemodified NSAIDs and valproic acid. Br J Pharmacol 151: 142- 151.
19. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58: 71- 96.
20. Jenuwein T, Allis CD. 2001. Translating the histone code. Science 293: 1074- 1080.
21. Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD. 2000. Chemoprotection by organosulfur inducers of phase 2 enzymes: Dithiolethiones and dithiins. Drug Metabol Drug Interact 17: 3- 22.
22. Kern DH, Morgan CR, Hildebrand-Zanki SU. 1988. In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: Synergy of antitumor activity with cisdiamminedichloroplatinum (II). Cancer Res 48: 117- 121.
23. Liu L, Wu J, Wu C, Wang Y, Zhong R, Zhang X, Tan W, Nie S, Miao X, Lin D. 2011. A functional polymorphism (-1607 1G→2G) in the matrix metalloproteinase-1 promoter is associated with development and progression of lung cancer. Cancer 117: 5172- 5181.
24. Ma X, Ezzeldin HH, Diasio RB. 2009. Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs 69: 1911- 1934.
25. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. 2005. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 65: 3815- 3822.
26. Marks PA, Richon VM, Miller T, Kelly WK. 2004. Histone deacetylase inhibitors. Adv Cancer Res 91: 137- 168.
27. McIntyre J, Moral MA, Bozzo J. 2007. Combination therapy with valproic acid in cancer: Initial clinical approach. Drugs Future 32: 45- 50.
28. Minucci S, Pelicci PG. 2006. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38- 51.
29. Moody TW, Switzer C, Santana-Flores W, Ridnour LA, Berna M, Thill M, Jensen RT, Sparatore A, Del Soldato P, Yeh GC, Roberts DD, Giaccone G, Wink DA. 2010. Dithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells. Lung Cancer 68: 154- 160.
30. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. 1996. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461- 462.
31. Myzak MC, Ho E, Dashwood RH. 2006. Dietary agents as histone deacetylase inhibitors. Mol Carcinog 45: 443- 446.
32. Myzak MC, Dashwood RH. 2006. Histone deacetylases as targets for dietary cancer preventive agents: Lessons learned with butyrate, diallyl disulfide, and sulforaphane. Curr Drug Targets 7: 443- 452.
33. Nishino N, Jose B, Okamura S, Ebisusaki S, Kato T, Sumida Y, Yoshida M. 2003. Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases. Org Lett 5: 5079- 5082.
34. Park HM, Cho JM, Lee HR, Shim GS, Kwak MK. 2008. Renal protection by 3H-1, 2-dithiole-3-thione against cisplatin through the Nrf2-antioxidant pathway. Biochem Pharmacol 76: 597- 607.
35. Parkin DM, Bray F, Ferlay J, Pisani P. 2005. Global cancer statistics, 2002. CA Cancer J Clin 55: 74- 108.
36. Perrino E, Cappelletti G, Tazzari V, Giavini E, Del Soldato P, Sparatore A. 2008. New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett 18: 1893- 1897.
37. Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T. 1998. Doxorubicin- and daunorubicin-glutathione conjugates, but not unconjugated drugs, competitively inhibit leukotriene C4 transport mediated by MRP/GS-X pump. Biochem Biophys Res Commun 247: 859- 863.
38. Reddy BS. 1996. Chemoprevention of colon cancer by minor dietary constituents and their synthetic analogues. Prev Med 25: 48- 50.
39. Reddy BS, Kawamori T, Lubet R, Steele V, Kelloff G, Rao CV. 1999. Chemopreventive effect of S-methylmethane thiosulfonate and sulindac administered together during the promotion/progression stages of colon carcinogenesis. Carcinogenesis 20: 1645- 1648.
40. Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F. 1998. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol 41: 385- 390.
41. Rosetti M, Tesei A, Ulivi P, Fabbri F, Vannini I, Brigliadori G, Amadori D, Bolla M, Zoli W. 2006. Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO- NSAID, in pancreatic cancer cell lines. Apoptosis 11: 1321- 1330.
42. Ruggeri BA, Robinson C, Angeles T, Wilkinson J IV, Clapper ML. 2002. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 8: 267- 274.
43. Sauter W, Rosenberger A, Beckmann L, Kropp S, Mittelstrass K, Timofeeva M, Wölke G, Steinwachs A, Scheiner D, Meese E, Sybrecht G, Kronenberg F, Dienemann H. LUCY-Consortium, Chang-Claude J, Illig T, Wichmann HE, Bickeböller H, Risch A, 2008. Matrix metalloproteinase 1 (MMP1) is associated with early onset lung cancer. Cancer Epidemiol Biomarkers Prev 17: 1127- 1135.
44. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N. 2000. Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 207: 77- 86.
45. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107- 1112.
46. Spiro SG, Silvestri GA. 2005. One hundred years of lung cancer. Am J Respir Crit Care Med 172: 523- 529.
47. Spiro SG, Porter JC. 2002. Lung cancer - where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 166: 1166- 1196.
48. Suzuki T, Kouketsu A, Matsuura A, Kohara A, Ninomiya S, Kohda K, Miyata N. 2004. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg Med Chem 14: 3313- 3317.
49. Su YW, Liang C, Jin HF, Tang XY, Han W, Chai LJ, Zhang CY, Geng B, Tang CS, Du JB. 2009. Hydrogen sulfide regulates cardiac function and structure in adriamycin-induced cardiomyopathy. Circ J 73: 741- 749.
50. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. 2010. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Hematol Oncol 3: 5.
51. Ueda K, Cardarelli C, Gottesman MM, Pastan I. 1987. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004- 3008.
52. Wedel SA, Sparatore A, Soldato PD, Al-Batran SE, Atmaca A, Juengel E, Hudak L, Jonas D, Blaheta RA. 2008. New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma. J Cell Mol Med 12: 2457- 2466.
53. Witt O, Deubzer HE, Milde T, Oeheme I. 2008. HDAC family: What are the cancer relevant targets? Cancer Lett 277: 8- 21.
54. Zoli W, Ricotti L, Tesei A, Barzanti F, Amadori D. 2001. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors. Crit Rev Oncol Hematol 37: 69- 82.